Horny finger-like lesions can be observed in many dermatoses. In some cases the clinical features suggest the diagnosis, but only the histological examination will confirm it. Our purpose here is to describe a case of multiple parakeratotic horns occurring in a patient with Crohn's disease.
A 7-year-old girl had a linear nevus comedonicus affecting the right upper limb. Histologic examination of two biopsies specimens showed both the common changes of nevus comedonicus and the presence of epidermolytic hyperkeratosis. Therefore, nevus comedonicus should be included in the list of dermatoses having the distinctive histologic pattern of epidermolytic hyperkeratosis.
A 42-year-old man with extensive white spongy lesions of the oral mucosa from childhood is reported. Histologic examination of two punch biopsies revealed many foci of epidermolytic hyperkeratosis. Similar lesions were present in one of his two brothers but he refused the biopsy. The problems of differential diagnosis are discussed.
Case of Eosinophilia Induced by EtretinateTo the Editor.\p=m-\The cutaneous side effects of etretinate are now well known, the most common being dryness of the mucosa, alopecia, palmoplantar hyperkeratosis, and pruritus.1,2 Certain metabolic abnormalities are also relatively common, such as the induction of hypertriglyceridemia and hypercholesterolemia as well as enzyme alterations, mainly of the transaminases and alkaline phosphatase.3,4 Moreover, etretinate therapy, like any other drug therapy, may be accompanied by allergic reactions and/or idiosyncratic effects.A case of hypersensitivity to etretinate therapy, marked by hyperpyrexia, eosinophilia, and hepatotoxic reaction, has recently been described.4 An example of suspected hypersensitivity to etretinate therapy is reported in this communication.Report of a Case.\p=m-\A71-year-old man was admitted for erythroderma of about two years' duration that was resistant to various attempts at treatment, including etretinate therapy, which had been received by the patient at irregular intervals for about two months. There was no evidence of familial or personal predisposition. The blood chemistry results disclosed neither enzyme alterations nor changes in the lipid metabolism. The blood cell counts and hematocrit values were both normal.In particular, there was no evidence of eosinophilia (leukocyte count, 4.1 X lO'/L [4100/mmJ]; eosinophil count, 0.041 X 10VL [41/mm3]). The clinical diagnosis was psoria¬ sis. This was confirmed histologically. Treatment with etretinate commenced as follows: 75 mg/d for two weeks, followed by 50 mg/d, with periodic blood chemistry checks.A slight initial improvement (reduction of erythema and itching) was followed by the appearance of eosinophilia (1.86 X 10VL [1863/mm3]), with no changes in the other values on the 28th day, and even higher levels (6.328 X 10V L [6328/mm3]) subsequently. This increase was accompa¬ nied by a gradual exacerbation of the clinical picture, with pronounced erythema and the appearance of edema (par¬ ticularly on the lower limbs) and signs of exudation. Pruritus also returned. In the days prior to the peak in the eosinophilia count, hyperpyrexia appeared (maximum temperature, 39°C). All tests performed to establish the cause of the eosinophilia proved negative, ie, stool para¬ sites, paper radioimmunosorbent test, radioallergosorbent test, hemagglutination for echinococcus, and roentgenograms of the chest and digestive tract. Computed tomographic scan of the liver revealed a roundish formation in the left lobe. This was interpreted as a cavernous hemangioma following the computed tomographic scan. Microscopic examination of the bone marrow aspirate did not disclose any red blood cells or granulocyte atypia in the bone marrow. These negative findings pointed to an iatrogenic effect.Etretinate administration was, therefore, suspended, and corticosteroid therapy was started in the form of 25 mg/d of prednisone. There was an appreciable improve¬ ment in the patient's clinical picture after a few days, together ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.